Pregled bibliografske jedinice broj: 675213
Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas – a pilot study
Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas – a pilot study // Pathology oncology research, 20 (2014), 3; 687-695 doi:10.1007/s12253-014-9749-y (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 675213 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas – a pilot study
Autori
Novak Kujundžić, Renata ; Grbeša, Ivana ; Ivkić, Mirko ; Krušlin, Božo ; Konjevoda, Paško ; Gall Trošelj, Koraljka
Izvornik
Pathology oncology research (1219-4956) 20
(2014), 3;
687-695
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
laryngeal squamous cell carcinoma; BORIS; transcript variant; immunohistochemistry; RT-PCR
Sažetak
BORIS is a paralog of a highly conserved, multi- functional chromatin factor CTCF. Unlike CTCF, which has been shown to possess tumor-suppressive properties, BORIS belongs to the “cancer/testis antigen” family normally expressed only in germ cells and aberrantly activated in a variety of tumors. The consequences of BORIS expression, relative abundance of its isoforms and its role in carcinogenesis have not been completely elucidated. It activates transcription of hTERT and MYC, genes relevant for laryngeal carcinoma progression. In this study, BORIS expression has been analyzed at transcriptional level by RT-PCR and protein level by semi-quantitative immunohistochemistry in 32 laryngeal squamous cell carcinomas and adjacent non-tumorous tissue. BORIS has been detected in 44% (14/32) laryngeal squamous cell carcinoma samples, while it has been detected only in one normal, tumor-adjacent tissue sample. Survival analysis, using recursive partitioning algorithm mvpart, has extracted the ratio of relative abundance of BORIS transcript variants containing exon 7 (BORIS 7+) and those lacking exon 7 (BORIS 7-) as an independent prognostic factor associated with the disease relapse during 5-years follow-up period. Patients having BORIS 7+/BORIS 7- ratio ≥1 had higher rate of disease relapse than patients with BORIS 7+/BORIS 7- ratio <1. Hazard ratio for that group, based on Cox Proportional Hazard Regression, was 3.53. This is the first study analyzing expression of BORIS protein and transcript variants in laryngeal squamous cell carcinoma relative to its possible prognostic value for recurrence and overall survival.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
098-0982464-2511 - Epigenetičke i imunomodulatorne promjene u zloćudnim tumorima glave i vrata (Gall-Trošelj, Koraljka, MZOS ) ( CroRIS)
108-1081870-1884 - Razvojna neuropatologija genetskih malformacija moždane kore čovjeka (Krušlin, Božo, MZOS ) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb
Profili:
Ivana Grbeša
(autor)
Koraljka Gall Trošelj
(autor)
Renata Novak Kujundžić
(autor)
Paško Konjevoda
(autor)
Mirko Ivkić
(autor)
Božo Krušlin
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE